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Abstract: Chronic pain in the elderly is a signiﬁ  cant problem. Pharmacokinetic and metabolic 
changes associated with increased age makes the elderly vulnerable to side effects and 
overdosing associated with analgesic agents. Therefore the management of chronic cancer 
pain and chronic nonmalignant pain in this growing population is an ongoing challenge. 
New routes of administration have opened up new treatment options to meet this challenge. 
The transdermal buprenorphine matrix allows for slow release of buprenorphine and damage 
does not produce dose dumping. In addition the long-acting analgesic property and relative 
safety proﬁ  le makes it a suitable choice for the treatment of chronic pain in the elderly. Its 
safe use in the presence of renal failure makes it an attractive choice for older individuals. 
Recent scientiﬁ  c studies have shown no evidence of a ceiling dose of analgesia in man but 
only a ceiling effect for respiratory depression, increasing its safety proﬁ  le. It appears that 
transdermal buprenorphine can be used in clinical practice safely and efﬁ  caciously for treating 
chronic pain in the elderly.
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Introduction
Many chronic pain patients are elderly (ie, 65 years of age) (Sittl 2006) and a 
signiﬁ  cant number of these experience chronic pain which can affect their normal 
functioning and quality of life (Gagliese and Melzack 1997). Difﬁ  culty in assessing 
the quality and intensity of pain due to cognitive changes and the presence of multiple 
medical problems associated with aging contributes to undertreatment of pain in 
this population. However, pharmacokinetic and metabolic changes associated with 
increased age make these patients more vulnerable to the potential side effects and 
overdosing with analgesic agents. Therefore, management of chronic pain due to cancer 
or persistent neuropathic pain (McQuay 2002; Foley 2003) is a challenge, especially 
in the growing population of elderly patients.
Chronic pain treatment in the elderly is multidimensional and includes noninvasive 
as well as invasive therapies. Invasive therapies include pharmacological therapies 
with nonopioid, opioid, and adjuvant medications. New routes of administration of 
drugs have opened up new treatment options for the treatment of chronic pain in the 
elderly (Grond et al 2000). In this context buprenorphine, a semi-synthetic, lipophilic, 
unique opioid analgesic, has broad clinical applications (Vadivelu and Hines 2007). 
Buprenorphine is being used sublingually (Book et al 2007) and intrathecally (Shah 
et al 2003) for the treatment of acute pain and transdermally for the treatment of 
chronic pain (Graziotti and Goucke 1997; Simpson 2002; Budd 2003; Likar et al 
2003). Its long-acting analgesic property and relative safety administered in this 
form make it useful for the treatment of chronic pain in the elderly. This review 
focuses on the use of transdermal buprenorphine for the treatment of chronic pain 
in the elderly.Clinical Interventions in Aging 2008:3(3) 422
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Chronic pain management 
in the elderly
Chronic pain increases with age (Crook et al 1984) due to 
increases in the incidence of diseases such as arthritis, can-
cer, diabetes mellitus, and cardiovascular and neurological 
diseases (Priano et al 2006). Detection and management of 
chronic pain in the elderly is often inadequate and continues 
to pose a challenge for practitioners (Woo et al 1994). The 
detection of chronic pain in the elderly can be done with 
a pain scoring pain system which assesses the severity of 
the patient’s pain subjectively on a score of from 1 to 10. 
The detection of pain in the elderly may be complicated 
by the presence depression and dementia. Dementia and 
confusion make the assessment of pain sometimes unreliable 
with resultant difﬁ  culty in applying the conservative and 
interventional therapies in these patients.
Elderly patients with depression report more pain than 
those who are not depressed (Casten et al 1995), and com-
plaints of pain may be the ﬁ  rst sign of dementia (Kisely et al 
1992). Chronic pain in the elderly can be either nociceptive 
or neuropathic. The conservative therapies for these states 
include adequate nutrition, cognitive and behavioral thera-
pies, rehabilitational pain medicine, biofeedback, relaxation, 
and alternative medicine techniques such as acupuncture and 
acupressure. Low level activity programs also can beneﬁ  t the 
elderly physically (Helme et al 1989).
Nonsteroidal anti-inﬂ  ammatory drugs are commonly 
used to treat nociceptive pain and inhibit prostaglandin pro-
duction. Malignant pain is often treated in the elderly with 
opioids which can be used also for treatment of neuropathic 
nonmalignant pain. Due to high fat to protein ratios, opioids 
in the elderly should be started at doses 25%–50% lower 
than those used in young adults, with rescue doses limited to 
5% of the total daily dose available every 4 hours (Abrahm 
2000). Commonly used opioids in the elderly are oxycodone, 
morphine, hydromorphone, and fentanyl patch. Oxycodone 
is a preferred drug in the elderly since it has a short half-life 
and no toxic metabolites, and is available in both the short- 
and long-acting forms. Morphine can be used with caution, 
paying attention to renal insufﬁ  ciency and sedation.
Common adjuvant medications for the treatment of 
nonmalignant neuropathic pain in the elderly include a 
variety of medications such as nonopioid analgesics, opioid 
analgesics, adjuvant medications including antidepressants, 
anticonvulsants, tramadol, and capsaicin. The invasive 
techniques include neuromodulatory or surgical interven-
tions such as nerve blocking, spinal cord stimulation and 
intraspinal, implantable drug delivery, and neurodestructive 
interventions. It is recommended that the least invasive and 
simple interventions be tried ﬁ  rst in the elderly before use 
of more invasive interventions.
Chronic pain control in the elderly by all these therapeutic 
measures is still inadequate. The recent development of 
transdermal buprenorphine has opened up new treatment 
options for treatment of chronic pain in this growing patient 
group. It has unique pharmacodynamics which could make 
it a useful analgesic in the presence of age-related cognitive, 
metabolic, and pharmacokinetic changes so often seen in the 
elderly. The pharmacokinetics of buprenorphine, especially its 
slow association and disassociation rate at the receptor sites, 
make it useful for use in the elderly (Yassen et al 2005).
Pharmacodynamics 
of buprenorphine
Originally, buprenorphine was thought to be 25–50 times 
more potent by weight than morphine in an equivalent dose 
(Jasinski et al 1978), but it is now thought that buprenor-
phine is 75–100 times more potent than morphine (Sittl 
et al 2006). Buprenorphine is a centrally acting partial mu 
agonist and a kappa and delta opioid receptor antagonist 
(Negus et al 2002). Buprenorphine has a high afﬁ  nity for 
the mu receptor and a lower intrinsic activity than a full 
agonist mu opioid receptor agonist (Cleeland et al 1994). 
It appears that the mu agonist effect is most important for 
producing its analgesic results. Buprenorphine can produce 
near maximal mu receptor occupation, thereby decreasing 
mu opioid receptor availability, and replace agonist effects 
and alleviate withdrawal symptoms (Greenwald et al 2003). 
Buprenorphine produces stabilization of mu receptors in the 
submembrane level and increases the expression of mu recep-
tors on membranes (Evans and Easthope 2003). By affecting 
the mu receptor, reserve buprenrophine can enable the switch 
from another opioid to buprenorphine. The mu agonist effect 
of buprenorphine is in the form of a bell-shaped curve. In 
animal models, the bell-shaped analgesic dose response 
curve peaks at 1 mg/kg, which is below the highest dose of 
32 mg/kg reported in humans.
Buprenorphine interacts with orphanin FQ/nociceptin 
receptor ORL-1 in the spinal cord and the brain stem. 
Buprenorphine activates ORL1 in the spinal cord, which 
appears to be analgesic. OR-1 activation in the brain stem 
blocks opioid analgesic responses and contributes to the partial 
agonist property of buprenorphine (Bloms-Funke et al 2000). 
Buprenorphine also possesses an antihyperalgesic effect 
relative to clinically used mu agonists; its antihyperalgesic 
effects exceed its analgesic effects (Simonnet and Rivat 2003; Clinical Interventions in Aging 2008:3(3) 423
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Koppert et al 2005; Simonnet 2005). It is thought that the 
antihyperalgesic effect of buprenorphine may be related to 
kappa opioid receptor blockade.
Buprenorphine is associated with a long duration of 
action, 6–8 hours (Johnson et al 2005), which has been 
attributed to the slow dissociation of buprenorphine from 
the mu receptor (Jasinski et al 1978). The transdermal 
buprenorphine formulation has a slow onset (12–24 hours) 
and a long duration of action (3 days) (Sorge and Sittl 2004). 
Increased sensitivity to the depressant actions of opioids in 
the elderly is well established. Fentanyl as a transdermal 
preparation is not recommended for used in opioid-naïve 
patients because of the incidence of respiratory depression 
(Thompson et al 1998).
Clinically relevant doses of up to 10 mg of buprenor-
phine have shown full dose-dependent effects on analgesia 
with no respiratory depression (Dahan et al 2005). Dahan 
et al (2006) have shown a ceiling to respiratory depression 
but not to analgesia over a dose range from 0.05 to 0.6 mg 
buprenorphine in humans This safety proﬁ  le could give 
transdermal buprenorphine a preferred role over transdermal 
fentanyl for treatment of chronic pain in the elderly. In 
humans, there is also a less marked effect of buprenorphine 
binding to mu opioid receptors on gastrointestinal transit 
times, and indeed constipation seen in the clinic is remarkably 
low (Griessinger et al 2005).
There was initial concern that the partial agonism of 
buprenorphine would lead to limited analgesia and would 
prevent other opioids from effectively binding. It has since 
been shown that buprenorphine is a strong analgesic, with 
no ceiling effect for analgesia (Jasinski et al 1978; Budd and 
Collett 2003). It does not produce persistent binding of the mu 
receptor, which would prevent the action of other opioids in 
acute and chronic painful conditions (Walsh et al 1995); as a 
result other opioids can be used for breakthrough pain in the 
presence of buprenorphine (Budd and Collett 2003).
Decreased tolerance
In humans exposed to opioids, but not physically depen-
dent on them, a study of volunteers receiving sublingual 
buprenorphine in ascending doses of 1 to 32 mg demon-
strated no ceiling effect for its analgesia effects (Walsh et al 
1994). In physically dependent individuals, acute cessation 
of buprenorphine may lead to withdrawal symptoms that 
appear to be milder than those seen with morphine (Heel 
et al 1979). Zaki et al (2000) studied equal concentrations 
(10 μM/L) of morphine, fentanyl, and buprenorphine, 
and showed that buprenorphine did not induce the loss of 
opioid receptors from the cell surface, as did morphine 
and fentanyl. Buprenorphine was unable to trigger mu 
receptor internalization because it has a low efﬁ  cacy for 
activating G proteins. Sittl et al (2005), who studied the use 
of transdermal fentanyl and transdermal buprenorphine in 
humans, found a signiﬁ  cant increase in the mean daily dose 
of fentanyl over buprenorphine in this time period. The long 
analgesic action of buprenorphine as well as its decreased 
tolerance because of loss of opioid receptors from the cell 
surface make it suitable the treatment of chronic pain in 
the elderly.
Metabolism and elimination
The metabolism of buprenorphine is mediated by cytochrome 
P450 in the liver (Heel et al 1979). Buprenorphine is oxidized 
to N dealkyl buprenorphine, also called norbuprenorphine by 
CYP3A4. Most opioids with the exception of buprenorphine 
and morphine undergo oxidation, and buprenorphine and 
morphine undergo glucuronidation. Both buprenorphine and 
norbuprinorphine undergo rapid glucuronidation. The bind-
ing to glucuronic acid leads to a low bioavailability of 5% 
with oral buprenorphine. Norbuprenorphine is 10 times more 
potent than buprenorphine in causing respiratory depression. 
However, this respiratory depressant effect of norbuprenor-
phine can be antagonized by naloxone (Gal 1989) and also 
by the substance beta-ﬂ  unaltrexamine. It also has a weak 
mu agonist effect that is seen after chronic use. Most of the 
concentration of norbuprenorphine has been seen in the lungs 
rather than in the brain (Ohtani et al 1997).
Buprenorphine is metabolized to glucuronide metabolites 
which can be hydrolyzed in the intestine to release buprenor-
phine again. The released buprenorphine can be reabsorbed 
via the enterohepatic circulation. Excretion of buprenorphine 
and metabolites is 70% by feces of unchanged buprenor-
phine, conjugated buprenorphine, and the Phase I conjugated 
metabolites. The other small quantity of buprenorphine-
related substances is excreted in the urine (Budd 2003). 
Unconjugated buprenorphine does not appear in urine, only 
in stool secondary to fecal ﬂ  ora beta-glucuronidase (Cone 
et al 1984).
Age-related changes in drug kinetics 
and dynamics relevant to opioids
The narrowing of the therapeutic index because of 
physiological changes in aging can alter the pharmacokinetics 
and pharmacodynamics of analgesics. Important changes are 
seen with age which can affect opioid drug kinetics and 
dynamics. Hepatic blood flow decreases with age and Clinical Interventions in Aging 2008:3(3) 424
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age-related changes occur in cytochromes and conjugases 
are. These changes can narrow the therapeutic index and 
increase the risk of toxicity and drug-drug interactions 
(Davis and Srivastava 2003). Distribution of drugs to the 
central nervous system (CNS) are altered with alterations in 
receptors and transmitters. These CNS changes can increase 
risk of delirium. In addition changes in renal function can 
be age-related.
Buprenorphine in the presence 
renal impairment
Renal impairment leading to a decrease in renal excretory 
function is common in elderly patients due to advanced age 
(Balázs et al 2008) or to co-morbid conditions such as dia-
betes or hypertension. Buprenorphine for treatment of pain 
can be administered in normal doses in the elderly, because 
it is excreted mainly in the liver (Brewster et al 1981; Cone 
et al 1984). In contrast, most opioids have to be cleared by 
the kidney and so have to be used in smaller doses, or with 
decreased frequency or not used at all in the elderly. Though 
the levels of norbuprenorphine may be increased by continu-
ous intravenous infusions of buprenorphine in renal failure 
(Summerﬁ  eld et al 1985), it most likely does not produce 
untoward effects because of the lower potency and lower 
afﬁ  nity of norbuprenorphine compared with buprenorphine 
(Hand et al 1990). Buprenorphine can be used in elderly 
patients with impaired renal function and chronic renal 
insufﬁ  ciency, and in hemodialysis patients in whom its phar-
macokinetics are unchanged. Filitz et al (2006) studied the 
disposition of buprenorphine and its metabolite norbuprenor-
phine in 10 patients with end-stage kidney disease treated 
with transdermal buprenorphine. The blood samples studied 
showed no increase in levels of buprenorphine and norbu-
prenorphine at up to 70 μg/hour transdermal buprenorphine. 
Stable analgesic effects as seen by unchanged buprenorphine 
plasma levels in the presence of hemodialysis were also seen 
in the presence of a transdermal buprenorphine patch. Its 
safety for use in the presence of renal impairment is a major 
advantage over other opioids in the elderly.
Buprenorphine in hepatic disease
Buprenorphine at high doses increases liver enzymes due to 
accumulation within mitochondria. Liver function is impor-
tant because buprenorphine is metabolized by CYP3A4, 
resulting in norbuprenorphine. Both are rapidly glucuroni-
dated by UCT1A1 and UGT2B7, and these processes occur 
in the liver. Unconjugated buprenorphine is excreted in the 
bile (Kintz 2002; Clarot et al 2003).
Buprenorphine pharmacokinetics are stable in mild to 
moderate hepatic impairment (Johnson et al 2005).
Side effects
Buprenorphine can cause nausea, vomiting, sedation, 
euphoria, papillary constriction, delayed gastric emptying, 
and respiratory depression. Buprenorphine in high doses 
can increase liver enzymes due to accumulation within 
mitochondria.
Sedation should be observed with the use of buprenorphine 
because sedatives are known to cause pharmacodynamic 
interactions (Clarot et al 2003). In humans, dose-response studies 
on respiratory depressive response showed data characterized 
by a bell-shaped curve in which respiratory depression response 
increases with increasing dose of buprenorphine in the lower 
dose ranges (Walsh et al 1995). This bell-shaped effect for 
respiratory depression suggests a decreased likelihood of 
respiratory depression with buprenorphine at higher doses, 
suggesting increased safety of the drug. The same bell-shaped 
curve has not been shown for the other buprenorphine-related 
mu opioid agonist effects of analgesia, euphoria, sedation, and 
papillary constriction (Jasinski et al 1978). Nausea, vomiting, 
and constipation can occur with buprenorphine as with other 
opioids; however, it has been shown that these side effects 
occur signiﬁ  cantly less with buprenorphine than with morphine 
(Walsh et al 1994).
Comparison of side effects 
with other opioids
Buprenorphine appears to have a greater margin of safety 
than other potent opioids such as fentanyl when used to treat 
chronic pain. Dahan et al (2005) compared the respiratory 
effects of buprenorphine and fentanyl given intravenously 
in healthy human volunteers. Buprenorphine-induced respi-
ratory depression had a maximum (ceiling) effect at doses 
of 0.1 mg/70 kg (Dahan et al 2005). In another study by 
Dahan et al (2006), a ceiling effect in respiratory depres-
sion, but not in analgesia, was demonstrated in a study on 
20 volunteers over a weight-adjusted dose range of 0.2–0.4 
mg/70 kg. The peak analgesic effect of buprenorphine was 
increased by doubling the dose, and the timing and magnitude 
of respiratory depression as seen by sedation and respira-
tory rate remained unchanged. Of note, its analgesic effect 
had no plateau. Buprenorphine may thus have full agonist 
effect for analgesia and a partial agonist effect for respira-
tory depression at mu receptors, showing a differential effect 
on analgesia and respiration. It appears that its respiratory 
effects are limited, unlike morphine and fentanyl which Clinical Interventions in Aging 2008:3(3) 425
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have been shown to have no ceiling effect for analgesia but 
which can cause severe respiratory depression and apnea in 
high doses. No detrimental effect from chronic exposure to 
buprenorphine has been shown on corticosensitive immune 
parameters (D’Elia et al 2003). Gomez-Flores and Weber 
(2000) showed that buprenorphine, unlike morphine, was 
not associated with immunosuppression and did not activate 
the hypothalamic–pituatary axis. The lack of effects on the 
immune system is thought to be related to its partial agonist 
effects.
Routes of administration
Several new routes for delivery of the buprenorphine are now 
available and have been used to provide analgesia, including 
the buprenorphine/naloxone combination and transdermal 
buprenorphine. The parenteral forms of buprenorphine, such 
as subcutaneous, intramuscular, epidural, and intrathecal, 
have been available since 1981. Sublingual buprenorphine 
has a much longer half-life than parenteral buprenorphine 
because of sequestration in buccal and sublingual fat. 
Because transdermal buprenorphine is not commercially 
available in the US, most clinicians who use the drug often 
convert from intravenous/subcutaneous infusions to sublin-
gual buprenorphine.
Buprenorphine is a lipophilic, synthetic opioid; these 
properties, combined with its low molecular weight, make 
it suitable for transdermal delivery. Average half-life is 37 
hours. Its properties of high afﬁ  nity and slow dissociation 
combined in a slow-release transdermal form can produce 
long-term pain relief with fewer side effects, making it suit-
able for treating persistent chronic pain of long duration in 
the elderly in whom wide swings of drug concentration are 
less well tolerated. Transdermal buprenorphine has a half-life 
of about 30 hours. Sublingual buprenorphine can be given 
for breakthrough pain. In a long-term study, sublingual 
buprenorphine was available for use as needed for control 
of pain (Likar and Sittle 2005).
The transdermal route is especially useful for drugs 
such as buprenorphine which have limited bioavailability if 
given orally. Transdermal buprenorphine can provide pain 
relief for cancer and for chronic noncancer pain (Likar et al 
2003; Pavelka et al 2004; Muriel et al 2005). Transdermal 
buprenorphine formulated in an adhesive polymer matrix 
(acrylate vinyl acetate) is being widely used clinically for 
the treatment of moderate to severe cancer pain (Budd and 
Collett 2003; Sittl et al 2006). The transdermal buprenorphine 
patch available in matrix form does not allow for dose dump-
ing in the event of damage to the patch and also improves 
patient compliance, an extremely important factor in elderly 
patients (Parikh 2007).
The purpose of the transdermal patch is to provide long-
term pain relief and to avoid an increase in adverse side 
effects. The transdermal buprenorphine patch is available in 
3 strengths, containing 20, 30, or 40 mg of buprenorphine, 
which can deliver 35, 52.5, or 70 μg/hour over 72 hours, 
respectively. It is generally recommended that patients 
who have not taken any analgesic or a nonopioid analgesic 
should start with a 35 μg/hour patch. This long-acting form 
of buprenorphine can be supplemented with the short-acting 
form of sublingual buprenorphine for breakthrough pain. If 
the patch is used, the time to minimum therapeutic concentra-
tion is 21 hours. After the placement of a transdermal patch 
additional analgesics should be available as needed for 24–48 
hours for treatment of breakthrough pain, because plasma 
levels of buprenorphine rise slowly after patch application. 
All opioid-naïve patients, especially the elderly, should be 
started with the lowest strength patch.
Transdermal buprenorphine 
for treatment of chronic pain
Transdermal buprenorphine has been shown to be useful for 
the treatment of chronic pain associated with cancer as well 
as noncancer etiologies (Sittl et al 2003). Likar et al (2003) 
studied the analgesic efﬁ  cacy and tolerability of transder-
mal buprenorphine in patients with inadequately controlled 
chronic pain. They demonstrated that buprenorphine is an 
effective analgesic for chronic pain. It was shown that trans-
dermal buprenorphine patches are useful for the treatment of 
moderate to severe cancer pain and also for noncancer pain 
that is severe and unresponsive to nonopioid analgesics. 
About one third of study patients with chronic pain had 
satisfactory analgesia with the administration of buprenor-
phine. In addition transdermal buprenorphine was found to 
decrease the need for rescue medications and increases the 
duration of pain-free sleep. Likar et al (2006) also studied 
the efﬁ  cacy and tolerability of long-term treatment with 
transdermal buprenorphine patients with chronic persistent 
pain of moderate to severe intensity who had previously 
received buprenorphine in 3 short-term clinical trials. They 
studied 134 patients with cancer-related pain and 105 patients 
with pain of noncancerous origin. The mean duration of 
participation was 7.5 months and the adherence to therapy 
was 78.7%. This level of adherence to therapy would be of 
particular help in the elderly.
Neuropathic pain or chronic persistent pain often presents 
as burning, lancinating pain caused by injury or chronic Clinical Interventions in Aging 2008:3(3) 426
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changes to peripheral or central nerves (McQuay 2002) and 
has been found to be difﬁ  cult to treat with conventional 
analgesics (Foley 2003). There is increasing evidence 
that opioids can decrease neuropathic pain in peripheral 
and central areas though the response can be variable 
(Rowbotham et al 2003). For example morphine, a typical 
mu opioid agonist, is not very sensitive in treating neuro-
pathic pain (Mao et al 1995). It has been suggested that the 
ineffectiveness of morphine in controlling neuropathic pain 
may be due to the downregulation of opioid receptors after 
nerve injury in the sensory neurons and in the spinal cord 
(Zhang et al 1998). In contrast, buprenorphine, a stronger 
opioid, has been shown in rats and humans to be effective in 
controlling neuropathic pain. It is known that some opioids 
have an NMDA blocking effect. Ebert et al (1995, pp. 165–8) 
have shown that buprenorphine is one such opioid that can 
block NMDA receptors and reduce reﬂ  ex facilitation and 
central sensitization (Kouya et al 2002).
Mechanical and cold allodynia and hyperalgesia were 
alleviated in rats with neuropathic pain behaviors (Kouya 
et al 2002). Human studies have also shown similar results. 
Intravenous buprenorphine has been shown to relieve long-
term neuropathic pain in patients after thoracotomy (Benedetti 
et al 1998). In another study, phantom limb pain was relieved 
by intrathecal buprenorphine after amputation (Omote et al 
1995). Buprenorphine given by the transdermal route has also 
providef adequate pain relief in cases of neuropathic pain, 
as shown in 3 patients with chronic nonmalignant pain due 
to musculoskeletal diseases (Balint 2002).
Transdermal buprenorphine has been used for “opioid 
rotation”, which is a method to treat chronic pain refractory 
to treatment by other opioids for long-term pain relief. In a 
opioid rotation study (Freye et al 2007), 42 patients (mean 
age 64.1 years) receiving high-dose morphine (120–240 
mg/day) for chronic pain secondary to neuropathic, mus-
culoskeletal, or malignant etiology were switched to trans-
dermal buprenorphine because of intolerable side effects 
and insufﬁ  cient pain relief. The patients were followed for 
more than 10 weeks. Patients reporting very good pain relief 
increased from 5% to 75% and those reporting improved 
quality of sleep increased from 14% to 74%. There was no 
tolerance to buprenorphine via this route and only 11.9% 
of adverse effects were noted, mostly due to local irrita-
tion. Chronic pain of cancer and noncancer origin was also 
reported to be effectively treated in all ages 70 years in 
another study by Griessinger et al (2005), in which a total 
of 13,179 chronic pain patients were evaluated. In this 
study 28% had cancer pain and 72% had noncancer pain. 
No development of tolerance was seen clinically in these 
patients and the patches were well tolerated. In a randomized 
controlled study by Pace et al (2007), patients with chronic 
cancer had better pain control, and improved mental health 
and vitality with the use of transdermal buprenorphine 
compared with sustained-release morphine. Transdermal 
buprenorphine appears to be well tolerated and effective 
for the treatment of chronic cancer and chronic noncancer 
pain in the long term.
Advantages in the elderly
Elderly patients need special consideration with several fac-
tors related to drug delivery, including drug delivery itself, 
drug interactions, and adherence to prescribed regimens. 
Transdermal drug delivery systems have advantages over 
other routes of drug administration especially in the elderly 
(Pepe et al 1988). The transdermal route is suited for the 
elderly as it provides ease of use for the patient and the care-
taker, provides greater adherence to prescribed regimens, and 
has less risk of toxicity and dose dumping. This is especially 
important because of the increased need for medications in 
older age when there is a higher incidence of chronic condi-
tions such as chronic pain, diabetes mellitus, cardiovascular 
disease, and neurological diseases such as Parkinson’s dis-
ease and Alzheimer’s disease. A transdermal delivery system 
is also useful when elderly patients are unable to tolerate 
oral medications or are unwilling to swallow oral medica-
tions. Transdermal medications also avoid needle punctures 
associated with subcutaneous or intravenous routes and are 
less labor intensive than these routes (Jiang et al 1997). It 
has been stated that transdermal delivery results in reason-
ably constant plasma drug concentrations because of its rate 
controlled delivery.
Transdermal buprenorphine has several advantages over 
the conventional methods of administration in the elderly: 
it results in no peak trough effects and a slower increase in 
serum concentration, resulting in fewer adverse events in 
serum concentrations compared with sublingual buprenor-
phine (Bohme 2002; Johnson et al 2005). The use of drugs 
with an absence of peak trough effects is in accordance with 
WHO guidelines, which recommend that to decrease adverse 
side effects, drugs should be used to treat chronic pain that 
do not induce sudden peaks in serum concentrations. The 
absorption of transdermal buprenorphine among patients 
varies less than among patients on transdermal fentanyl 
(Jensen et al 2007). Transdermal fentanyl absorption has 
been thought to decrease in the elderly, resulting in many 
dose adjustments. Since the absorption of transdermal Clinical Interventions in Aging 2008:3(3) 427
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buprenorphine is little affected with age, its relative potency 
will increase in the elderly. It has been suggested that fewer 
dosage adjustments are needed in patients using transdermal 
buprenorphine compared with patients using transdermal 
fentanyl. This was shown in a retrospective analysis on data 
from 400 medical practices in Germany which showed a 
signiﬁ  cantly greater increase in mean daily dosage in patients 
treated with transdermal fentanyl compared with patients 
treated with transdermal buprenorphine (Sittl et al 2006). 
The painful conditions included cancer, osteoarthritis, low 
back pain, and osteoporosis.
The reduced need to escalate transdermal buprenor-
phine relative to transdermal fentanyl is probably related 
to the antihyperalgesic effect, which prevents or blocks 
hyperadaptive responses differing from fentanyl (Célèrier 
et al 2000; Angst et al 2003; Koppert et al 2005). Incidence 
of chronic pain conditions increases with advancing age. 
Increased back pain due to osteoporotic and compression 
fractures are common in the elderly (Gandy and Payne 
1986) and transdermal buprenorphine, by virtue of its dos-
age stability, could be used to treat these conditions safely 
in the elderly.
The low incidence of adverse events associated with 
buprenorphine lends an added attraction for use in the 
elderly who have decreased tolerance to adverse effects. 
In the elderly the transdermal patch is ideal because it can 
be easily applied, resulting in greater compliance in this 
population who tend to be more forgetful. It also has a lower 
susceptibility to the development of toxicity and opioid abuse 
because it adheres strongly and is less susceptible to damage 
(Budd 2003).
Less respiratory depression
Because of its partial agonist activity and the associated 
ceiling effect in respiratory depression (Walsh et al 1995), 
transdermal buprenorphine is useful for treatment in the 
elderly who are more prone to respiratory depression asso-
ciated with common respiratory diseases such as chronic 
bronchitis, emphysema, and chronic obstructive pulmonary 
disease. Downing et al (1979) studied 10 critically ill patients 
in whom intravenous buprenorphine 0.2–0.4 mg had no 
signiﬁ  cant effect on base excess values, oxygen saturation, 
or heart rate. It did, however, increase the arterial carbon 
dioxide levels and reduce respiratory rate in these patients. 
A large study in 3,690 cancer patients (44% of whom were 
70 years of age) clearly showed the effectiveness and 
safety of the transdermal buprenorphine patch in the elderly 
(Griessinger et al 2005).
Long duration of action
The high afﬁ  nity to the mu receptor enables buprenorphine 
to exert its analgesic effect for a long duration, eliminating 
the need for daily dosing and overcoming problems of non-
adherence to treatment regimens which is common in the 
elderly. This property will also decrease the risk of death 
by overdose.
Drug interactions in the elderly
To establish specific safety guidelines, the use of 
buprenorphine in the elderly with other drugs requires 
further investigation, especially as many elderly patients 
are using many different pharmacological agents such 
as treatment for heart disease and cognitive dysfunction. 
Common medications of the elderly include beta blockers, 
statins, and ACE-inhibitors. Buprenorphine has been known 
to inhibit the cytochrome P 450 system by inhibiting the 
CYP3A4- and CYP2D6-mediated reactions. It is thought, 
however, that the clinical concentrations used are unlikely to 
affect signiﬁ  cantly metabolism of drugs that are metabolized 
by cytochrome P 450 (Umehara et al 2002). It is known 
than CYP3A4 and UCTiA3 are relatively preserved in the 
elderly. Drugs that interact with CYP3A4 will not prevent 
conjugation, which is rate limiting. Buprenorphine interacts 
with CYP3A4 differently than methadone. It is seem 
that ﬂ  uvoxamine, which blocks CYP3A4 and methadone 
metabolism, does not interfere with buprenorphine clearance 
(Iribarne et al 1998).
Buprenorphine cannot be dialyzed and very high doses 
of naloxone are sometimes needed to reverse respiratory 
depression (Orwin et al 1976; Knape 1986; Gal 1989), 
because of the high afﬁ  nity of buprenorphine to the mu 
receptor as well as the slow dissociation from the receptor. 
Respiratory depression with the use of buprenorphine, 
except after the intraspinal route (Chrubasik et al 
1994), is very rare (Ventafridda et al 1983). It must be 
remembered that concomitant exposure to other drugs that 
can induce or inhibit the enzyme may intensify the action 
of buprenorphine. Opioids, anesthetic agents, sedatives, 
hypnotics, monoamine oxidase inhibitors, antidepressants, 
neuroleptics, and alcohol can intensify the CNS effects of 
buprenorphine.
Disadvantages in the elderly
To avoid opioid toxicity symptoms, buprenorphine should be 
used with caution when it is being used with other drugs such 
as benzodiazepines. This interaction with benzodiazepines 
can occur with all opioids and is related to the synergistic Clinical Interventions in Aging 2008:3(3) 428
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effect on the CNS causing sedation and respiratory 
depression. This effect is not due to hepatic metabolism 
(Ibrahim et al 2000).
Lai and Teo (2006) studied 21 buprenorphine-related 
deaths in Singapore. In 19 of these deaths buprenorphine and 
benzodiazepines were being used concurrently, suggesting 
that their concurrent use could be fatal. All these individuals 
were under the age of 40 years. Therefore, benzodiazepines 
should be prescribed with caution in the elderly. It has been 
reported that intravenous use of buprenorphine combined 
with benzodiazepines has resulted in some deaths (Reynaud 
et al 1998). In the event of respiratory depression when 
transdermal buprenorphine and benzodiazepines are used 
concurrently, the treatment would include respiratory support 
with mechanical ventilation if necessary until buprenorphine 
is completely metabolized.
Buprenorphine and drug 
dependence
Buprenorphone is licensed to treat drug dependence. In 
the large experience published, there are fewer deaths with 
buprenorphine maintenance therapy than with methadone. If 
a patient with cancer and opioid dependence or a history of 
drug abuse had pain, buprenorphine would be a reasonable 
choice in combination with naloxone.
Use in the presence of cognitive 
disorders
In the elderly suffering from cognitive and motor deﬁ  cits as 
a result of chronic neurological diseases such as Parkinson’s 
disease and Alzheimer’s disease, transdermal buprenorphine 
will be a useful tool for the administration of drugs when 
patients are forgetful, or unwilling or unable to swallow oral 
medications. Cumbersome equipment associated with the use 
of intravenous of subcutaneous infusions can also be avoided. 
Rate-controlled delivery through the transdermal route leads 
to constant plasma concentrations of the drug irrespective of 
the drug’s half-life.
Buprenorphine is metabolized by the liver by glucuroni-
dation and not oxidation, and should be used in caution with 
elderly patients with hepatic disease such as cirrhosis, though 
glucuronidation is less affected by liver disease than is oxi-
dation of opioids. In patients with increased temperature, 
additional monitoring may be required since increased body 
temperature can increase skin permeability. Conditions where 
buprenorphine are contraindicated are patients with opioid 
dependence, myasthenia gravis, respiratory depression, and 
delirium tremens.
Future research
In addition to cancer and arthritis, there are several chronic 
neuropathic pain syndromes that occur more commonly 
with advancing age. These include post-herpetic neuralgia 
(Bowsher 1999), diabetes, and strokes. Long-standing 
diabetes could lead to painful diabetic neuropathy, and 
strokes can be followed by post-stroke pain. The use of 
transdermal buprenorphine in these settings will require 
further evaluation.
Conclusion
Chronic pain in the elderly is a signiﬁ  cant problem and 
the age-related metabolic, cognitive, and pharmacokinetic 
changes associated with advanced age make pain control 
in the elderly a challenge. The transdermal buprenorphine 
matrix allows for slow release of buprenorphine, and dam-
age does not produce dose dumping, which is an added 
advantage especially in the elderly (Budd 2003). The high 
incidence of coexisting diseases such as diabetes, cardio-
vascular, and neurological diseases in the elderly raises 
concerns of drug interactions with multiple medications. In 
addition the elderly need special consideration for adherence 
to medication regimen and drug delivery (Priano et al 2006). 
The recently developed transdermal buprenorphine, with 
its unique pharmacodynamics and special matrix formula-
tion, shows promise for the control of this difﬁ  cult problem 
in the elderly. The pharmacodynamics of buprenorphine 
shows that it has several advantages for use in the elderly. 
Scientiﬁ  c studies have signiﬁ  cantly refuted misconcep-
tions of buprenorphine in the past, such as the inability to 
produce adequate analgesia because of its partial agonist 
effect, the ineffectiveness of other opioids to act in the pres-
ence of buprenorphine, and the concern that if respiratory 
depression occurred it could not be reversed with naloxone. 
Recent scientiﬁ  c studies with buprenorphine have shown no 
evidence of a ceiling dose of analgesia in humans but only a 
ceiling effect for respiratory depression (Walsh et al 1995), 
suggesting a low abuse liability and increased safety. Its 
mu agonist properties of long duration exist for analgesia, 
sedation, euphoria, and papillary constriction. Naloxone 
has been found to reverse any respiratory depression caused 
by buprenorphine (Gal 1989). The safe and effective use 
of transdermal buprenorphine in the presence of renal 
failure makes it an attractive choice for older individuals 
who have a higher predisposition for the development of 
renal insufﬁ  ciency. In addition the low potential for drug 
to drug interaction along with the beneﬁ  cial effects on the 
immune system makes it a suitable opioid for use in the Clinical Interventions in Aging 2008:3(3) 429
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elderly (Griessinger et al 2005). It must be remembered, 
however, that buprenorphine and transdermal buprenorphine 
could be associated with sedation and the elderly should be 
monitored carefully for this side effect. In addition buprenor-
phine should be used with caution with other drugs such as 
benzodiazepines. More outcome studies are needed on the 
effectiveness of transdermal buprenorphine for control of 
chronic pain associated with conditions more commonly 
seen in the elderly such as diabetic neuropathy, post-stroke 
pain, and post-herpetic neuralgia.
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